iScience (Sep 2023)
BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine
- Dilhan J. Perera,
- Pilar Domenech,
- George Giorgi Babuadze,
- Maedeh Naghibosadat,
- Fernando Alvarez,
- Cal Koger-Pease,
- Lydia Labrie,
- Matthew Stuible,
- Yves Durocher,
- Ciriaco A. Piccirillo,
- André Lametti,
- Pierre Olivier Fiset,
- Seyyed Mehdy Elahi,
- Gary P. Kobinger,
- Rénald Gilbert,
- Martin Olivier,
- Robert Kozak,
- Michael B. Reed,
- Momar Ndao
Affiliations
- Dilhan J. Perera
- Division of Experimental Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada
- Pilar Domenech
- Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; McGill International TB Centre, McGill University, Montréal, QC, Canada
- George Giorgi Babuadze
- Department of Biological Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA
- Maedeh Naghibosadat
- Department of Biological Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
- Fernando Alvarez
- Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada
- Cal Koger-Pease
- Division of Experimental Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada
- Lydia Labrie
- Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada
- Matthew Stuible
- Department of Production Platforms & Analytics, Human Health Therapeutics Research Center, National Research Council Canada, Montréal, QC, Canada
- Yves Durocher
- Department of Production Platforms & Analytics, Human Health Therapeutics Research Center, National Research Council Canada, Montréal, QC, Canada
- Ciriaco A. Piccirillo
- Division of Experimental Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada
- André Lametti
- Department of Pathology, McGill University, Montréal, QC, Canada
- Pierre Olivier Fiset
- Department of Pathology, McGill University, Montréal, QC, Canada
- Seyyed Mehdy Elahi
- Department of Production Platforms & Analytics, Human Health Therapeutics Research Center, National Research Council Canada, Montréal, QC, Canada
- Gary P. Kobinger
- Département de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, QC, Canada
- Rénald Gilbert
- Department of Production Platforms & Analytics, Human Health Therapeutics Research Center, National Research Council Canada, Montréal, QC, Canada
- Martin Olivier
- Division of Experimental Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada
- Robert Kozak
- Department of Biological Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Corresponding author
- Michael B. Reed
- Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; McGill International TB Centre, McGill University, Montréal, QC, Canada; Corresponding author
- Momar Ndao
- Division of Experimental Medicine, McGill University, Montréal, QC, Canada; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada; Department of Microbiology and Immunology, McGill University, Montréal, QC, Canada; National Reference Centre for Parasitology, McGill University Health Centre, Montréal, QC, Canada; Corresponding author
- Journal volume & issue
-
Vol. 26,
no. 9
p. 107612
Abstract
Summary: Recent publications have explored intranasal (i.n.) adenovirus-based (Ad) vaccines as an effective strategy for SARS-CoV-2 in pre-clinical models. However, the effects of prior immunizations and infections have yet to be considered. Here, we investigate the immunomodulatory effects of Mycobacterium bovis BCG pre-immunization followed by vaccination with an S-protein-expressing i.n. Ad, termed Ad(Spike). While i.n. Ad(Spike) retains some protective effect after 6 months, a single administration of BCG-Danish prior to Ad(Spike) potentiates its ability to control viral replication of the B.1.351 SARS-CoV-2 variant within the respiratory tract. Though BCG-Danish did not affect Ad(Spike)-generated humoral immunity, it promoted the generation of cytotoxic/Th1 responses over suppressive FoxP3+ TREG cells in the lungs of infected mice. Thus, this vaccination strategy may prove useful in limiting future pandemics by potentiating the long-term efficacy of mucosal vaccines within the context of the widely distributed BCG vaccine.
